Nano-TRAIL: a promising path to cancer therapy

Abstract

Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand, also called apo-2 ligand (TRAIL/Apo-2L), is a cytokine that triggers apoptosis by binding to TRAIL-R1 (DR4) and TRAIL-R2 (DR5) death receptors. Apoptosis occurs through either the extrinsic or intrinsic pathway. The administration of recombinant human TRAIL (rhTRAIL) or TRAIL-receptor (TRAIL-R) agonists promotes apoptosis preferentially in cancerous cells over normal cells in vitro; this phenomenon has also been observed in clinical studies. The limited efficacy of rhTRAIL in clinical trials could be attributed to drug resistance, short half-life, targeted delivery issues, and off-target toxicities. Nanoparticles are excellent drug and gene delivery systems characterized by improved permeability and retention, increased stability and biocompatibility, and precision targeting. In this review, we discuss resistance mechanisms to TRAIL and methods to overcome TRAIL resistance by using nanoparticle-based formulations developed for the delivery of TRAIL peptides, TRAIL-R agonists, and TRAIL genes to cancer cells. We also discuss combinatorial approaches of chemotherapeutic drugs with TRAIL. These studies demonstrate TRAIL’s potential as an anticancer agent.

Keywords

TRAIL / cancer cells / nanoparticles / apoptosis / nanomedicine

References

[1] Baskar R,Yeo R.Cancer and radiation therapy: current advances and future directions.Int J Med Sci2012;9:193-9 PMCID:PMC3298009

[2] Pucci C,Ciofani G.Innovative approaches for cancer treatment: current perspectives and new challenges.Ecancermedicalscience2019;13:961 PMCID:PMC6753017

[3] LeBlanc HN.Apo2L/TRAIL and its death and decoy receptors.Cell Death Differ2003;10:66-75

[4] Staniek J,Heller B.TRAIL-R1 and TRAIL-R2 mediate TRAIL-dependent apoptosis in activated primary human B lymphocytes.Front Immunol2019;10:951 PMCID:PMC6503035

[5] Ndebele K,Jin TG.Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induced mitochondrial pathway to apoptosis and caspase activation is potentiated by phospholipid scramblase-3.Apoptosis2008;13:845-56 PMCID:PMC2941895

[6] Pistritto G,Ceci C,D'Orazi G.Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies.Aging (Albany NY)2016;8:603-19 PMCID:PMC4925817

[7] Kiraz Y,Kartal Yandim M.Major apoptotic mechanisms and genes involved in apoptosis.Tumour Biol2016;37:8471-86

[8] Wang S.TRAIL and apoptosis induction by TNF-family death receptors.Oncogene2003;22:8628-33

[9] Kalkavan H.MOMP, cell suicide as a BCL-2 family business.Cell Death Differ2018;25:46-55 PMCID:PMC5729535

[10] Refaat A,Reda A.TRAIL combinations: The new ‘trail’ for cancer therapy (Review).Oncol Lett2014;7:1327-32 PMCID:PMC3997674

[11] Wiley SR,Smolak PJ.Identification and characterization of a new member of the TNF family that induces apoptosis.Immunity1995;3:673-82

[12] Hymowitz SG,Fuh G.Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5.Mol Cell1999;4:563-71

[13] Micheau O.Regulation of TNF-related apoptosis-inducing ligand signaling by glycosylation.Int J Mol Sci2018;19:715 PMCID:PMC5877576

[14] Naval J,Gallego-Lleyda A,Martinez-Lostao L.Importance of TRAIL molecular anatomy in receptor oligomerization and signaling. Implications for cancer therapy.Cancers2019;11:444 PMCID:PMC6521207

[15] Lemke J,Zinngrebe J.Getting TRAIL back on track for cancer therapy.Cell Death Differ2014;21:1350-64 PMCID:PMC4131183

[16] Trivedi R.Trailing TRAIL resistance: novel targets for TRAIL sensitization in cancer cells.Front Oncol2015;5:69 PMCID:PMC4382980

[17] Falschlehner C,Gerlach B.TRAIL signalling: decisions between life and death.Int J Biochem Cell Biol2007;39:1462-75

[18] Ralff MD.TRAIL pathway targeting therapeutics.Expert Rev Precis Med Drug Dev2018;3:197-204 PMCID:PMC6366666

[19] Li H,Xu C.Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis.Cell1998;94:491-501

[20] Luo X,Zou H,Wang X.Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors.Cell1998;94:481-90

[21] Du C,Li Y,Wang X.Smac, a mitochondrial protein that promotes cytochrome C-dependent caspase activation by eliminating IAP inhibition.Cell2000;102:33-42

[22] Loreto C,Anzalone R.The role of intrinsic pathway in apoptosis activation and progression in Peyronie’s disease.Biomed Res Int2014;2014:616149 PMCID:PMC4147380

[23] Snajdauf M,Vachtenheim J Jr.The TRAIL in the treatment of human cancer: an update on clinical trials.Front Mol Biosci2021;8:628332 PMCID:PMC8006409

[24] Wang K,Jeon M,Ellenbogen RG.Nanoparticle-mediated target delivery of trail as gene therapy for glioblastoma.Adv Healthc Mater2015;4:2719-26 PMCID:PMC4715716

[25] Zhang L.Mechanisms of resistance to TRAIL-induced apoptosis in cancer.Cancer Gene Ther2005;12:228-37

[26] Yin N,Khalid S,Sabitaliyevich UY.TRAIL mediated signaling in breast cancer: awakening guardian angel to induce apoptosis and overcome drug resistance. In: Ahmad A, editor. Breast cancer metastasis and drug resistance. Cham: Springer International Publishing; 2019. pp. 243-52.

[27] Dine JL,Gehlhaus K.Abstract 15: gp78 is a negative regulator of TRAIL-induced apoptosis in breast cancer cells.Cancer Res2015;75:15-15

[28] Deng D.TRAIL of hope meeting resistance in cancer.Trends Cancer2020;6:989-1001 PMCID:PMC7688478

[29] Dianat-Moghadam H,Mahari A.TRAIL in oncology: from recombinant TRAIL to nano- and self-targeted TRAIL-based therapies.Pharmacol Res2020;155:104716

[30] Singh D,Singh S.Revisiting the role of TRAIL/TRAIL-R in cancer biology and therapy.Future Oncol2021;17:581-96

[31] Zhang Y.TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.Mol Cancer Res2008;6:1861-71

[32] Artykov AA,Dolgikh DA,Trushina DB.Death receptors DR4 and DR5 Undergo spontaneous and ligand-mediated endocytosis and recycling regardless of the sensitivity of cancer cells to TRAIL.Front Cell Dev Biol2021;9:733688

[33] Shin MS,Lee SH.Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers.Cancer Res2001;61:4942-6

[34] Mérino D,Morizot A,Solary E.Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.Mol Cell Biol2006;26:7046-55 PMCID:PMC1592888

[35] Sanlioglu AD,Aydin C,Koksoy S.Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells.BMC Cancer2005;5:54 PMCID:PMC1156874

[36] Wagner KW,Januario T.Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.Nat Med2007;13:1070-7

[37] Dufour F,Shirley S.N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death.Cell Death Differ2017;24:500-10 PMCID:PMC5344210

[38] Yeh WC,McCurrach ME.FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis.Science1998;279:1954-8

[39] Kuang AA,Zhang J.FADD is required for DR4- and DR5-mediated apoptosis: lack of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts.J Biol Chem2000;275:25065-8

[40] Zang F,Leng X,Sun B.C-FLIP(L) contributes to TRAIL resistance in HER2-positive breast cancer.Biochem Biophys Res Commun2014;450:267-73

[41] Murtaza I,Adhami VM,Mukhtar H.Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells.Cancer Res2009;69:1156-65 PMCID:PMC2996261

[42] Hassanzadeh A,Alivand MR.Down-regulation of intracellular anti-apoptotic proteins, particularly c-FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL.J Cell Physiol2018;233:6470-85

[43] Woo SM,Seo SU.Axl inhibitor R428 enhances TRAIL-mediated apoptosis through downregulation of c-FLIP and survivin expression in renal carcinoma.Int J Mol Sci2019;20:3253 PMCID:PMC6651098

[44] Geserick P,Hupe M.Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis.Oncogene2008;27:3211-20

[45] Padmanabhan C,Zhu J.cFLIP critically modulates apoptotic resistance in epithelial-to-mesenchymal transition.Oncotarget2017;8:101072-86 PMCID:PMC5731856

[46] Zhang L,Teraishi F.Accelerated degradation of caspase-8 protein correlates with TRAIL resistance in a DLD1 human colon cancer cell line.Neoplasia2005;7:594-602 PMCID:PMC1501285

[47] Robert E,El-Deiry WS.Suppression of caspase-8- and -10-associated RING proteins results in sensitization to death ligands and inhibition of tumor cell growth. Proceedings of the National Academy of Science;2004 101 (16) 6170-6175 PMCID:PMC395941

[48] Gillissen B,Richter A.Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma.J Cell Biol2010;188:851-62 PMCID:PMC2845080

[49] Kandasamy K,Alnemri ES.Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release.Cancer Res2003;63:1712-21

[50] Sarosiek KA,Bachman JA.BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response.Mol Cell2013;51:751-65 PMCID:PMC4164233

[51] Han J,Gastman BR.Differential involvement of Bax and Bak in TRAIL-mediated apoptosis of leukemic T cells.Leukemia2004;18:1671-80

[52] Peña-Blanco A.Bax, Bak and beyond - mitochondrial performance in apoptosis.FEBS J2018;285:416-31

[53] Hilmi C,Giuliano S.IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin.J Invest Dermatol2008;128:1499-505

[54] Adem J,Eeva J,Pelkonen J.The combination of TRAIL and MG-132 induces apoptosis in both TRAIL-sensitive and TRAIL-resistant human follicular lymphoma cells.Leuk Res2018;66:57-65

[55] Lamothe B.Ectopic expression of Bcl-2 and Bcl-xL inhibits apoptosis induced by TNF-related apoptosis-inducing ligand (TRAIL) through suppression of caspases-8, 7, and 3 and BID cleavage in human acute myelogenous leukemia cell line HL-60.J Interferon Cytokine Res2002;22:269-79

[56] Fulda S,Debatin KM.Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression.Oncogene2002;21:2283-94

[57] Danish L,Allgöwer F,Pollak N.Bcl-2-mediated control of TRAIL-induced apoptotic response in the non-small lung cancer cell line NCI-H460 is effective at late caspase processing steps.PLoS One2018;13:e0198203 PMCID:PMC6013189

[58] Opel D,Schneider M,Debatin KM.Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma.Clin Cancer Res2011;17:3233-47

[59] Garimella SV,Dine JL.Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening.Breast Cancer Res2014;16:R41 PMCID:PMC4053258

[60] Werner TA,Dizdar L.IAPs cause resistance to TRAIL-dependent apoptosis in follicular thyroid cancer.Endocr Relat Cancer2018;25:295-308

[61] Pieczykolan JS,Masłyk M.AD-O53.2--a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L.Invest New Drugs2014;32:1155-66

[62] Zhang S,Zhao Y.Smac mimetic SM-164 potentiates APO2L/TRAIL- and doxorubicin-mediated anticancer activity in human hepatocellular carcinoma cells.PLoS One2012;7:e51461 PMCID:PMC3519882

[63] Saraei R,Movassaghpour Akbari AA,Hassanzadeh A.The role of XIAP in resistance to TNF-related apoptosis-inducing ligand (TRAIL) in Leukemia.Biomed Pharmacother2018;107:1010-9

[64] Jia L,Kelsey SM.Role of Smac in human leukaemic cell apoptosis and proliferation.Oncogene2003;22:1589-99

[65] Metwalli AR,Jinesh G.Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells.Cancer Biol Ther2010;10:885-92 PMCID:PMC3230293

[66] Wu MS,Zhao ZQ.Smac mimetics in combination with TRAIL selectively target cancer stem cells in nasopharyngeal carcinoma.Mol Cancer Ther2013;12:1728-37

[67] Dai Y,Tang W.A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB.BMC Cancer2009;9:392 PMCID:PMC2779195

[68] Zhang XD,Gray CP,Hersey P.Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria.Cancer Res2001;61:7339-48

[69] Li P,Yin D.EGCG sensitizes human nasopharyngeal carcinoma cells to TRAIL-mediated apoptosis by activation NF-κB.Neo2017;64:74-80

[70] Rasheduzzaman M,Park SY.Resveratrol sensitizes lung cancer cell to TRAIL by p53 independent and suppression of Akt/NF-κB signaling.Life Sci2018;208:208-20

[71] Liu PC,Deng Y.Inhibition of NF-κB pathway and modulation of MAPK signaling pathways in glioblastoma and implications for lovastatin and tumor necrosis factor-related apoptosis inducing ligand (TRAIL) combination therapy.PLoS One2017;12:e0171157 PMCID:PMC5279772

[72] Geismann C,Sebens S.c-Rel is a critical mediator of NF-κB-dependent TRAIL resistance of pancreatic cancer cells.Cell Death Dis2014;5:e1455 PMCID:PMC4237244

[73] Li SS,Wang SH,Yang XM.Simultaneously targeting bcl-2 and Akt pathways sensitizes nasopharyngeal carcinoma to tumor necrosis factor-related apoptosis-inducing ligand.Cancer Biother Radiopharm2012;27:88-95

[74] Xu J,Wei WZ.Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells.PLoS One2010;5:e10226 PMCID:PMC2856686

[75] Dida F,Iwao A,Azuma E.Resistance to TRAIL-induced apoptosis caused by constitutional phosphorylation of Akt and PTEN in acute lymphoblastic leukemia cells.Exp Hematol2008;36:1343-53

[76] Plastaras JP,Carroll K,Birnbaum MJ.Role of PI3K/Akt signaling in TRAIL- and radiation-induced gastrointestinal apoptosis.Cancer Biol Ther2008;7:2047-53

[77] Goncharenko-Khaider N,Matte I,Piché A.The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells.Oncogene2010;29:5523-36 PMCID:PMC3007125

[78] Cao L,Jiang SH,Huang QL.Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature.Mol Cancer Ther2008;7:851-61

[79] Bellail AC,Mulligan P,Hao C.TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges.Rev Recent Clin Trials2009;4:34-41

[80] ClinicalTrials.gov. A study of AMG 951 [rhApo2L/TRAIL] in subjects with previously untreated non-small cell lung cancer (NSCLC) treated with chemotherapy +/- bevacizumab. Available from: https://clinicaltrials.gov/ct2/show/NCT00508625 [Last accessed on 30 Jan 2023]

[81] ClinicalTrials.gov. A study of dulanermin administered in combination with the FOLFOX regimen and bevacizumab in patients with previously untreated, locally advanced, recurrent, or metastatic colorectal cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT00873756 [Last accessed on 30 Jan 2023]

[82] ClinicalTrials.gov. A phase III trial of recombinant human Apo-2 ligand for injection. Available from: https://clinicaltrials.gov/ct2/show/NCT03083743 [Last accessed on 30 Jan 2023]

[83] ClinicalTrials.gov. Study of Mapatumumab in combination with bortezomib (Velcade) and bortezomib alone in subjects with relapsed or refractory multiple myeloma. Available from: https://clinicaltrials.gov/ct2/show/NCT00315757 [Last accessed on 30 Jan 2023]

[84] ClinicalTrials.gov. Study of mapatumumab in combination with Sorafenib in subjects with advanced hepatocellular carcinoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01258608 [Last accessed on 30 Jan 2023]

[85] ClinicalTrials.gov. A study of mapatumumab in combination with paclitaxel and carboplatin in subjects with non-small cell lung cancer (NSCLC). Available from: https://clinicaltrials.gov/ct2/show/NCT00583830 [Last accessed on 30 Jan 2023]

[86] ClinicalTrials.gov. Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects with relapsed or refractory Non-Hodgkin’s lymphoma (NHL). Available from: https://clinicaltrials.gov/ct2/show/NCT00094848 [Last accessed on 30 Jan 2023]

[87] ClinicalTrials.gov. CS-1008 with carboplatin/paclitaxel in chemotherapy naïve subjects with metastatic or unresectable non-small cell lung cancer (NSCLC). Available from: https://clinicaltrials.gov/ct2/show/NCT00991796 [Last accessed on 30 Jan 2023]

[88] ClinicalTrials.gov. Open-label study of CS-1008 for subjects with untreated and unresectable pancreatic cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT00521404 [Last accessed on 30 Jan 2023]

[89] ClinicalTrials.gov. Abraxane with or without tigatuzumab in patients with metastatic, triple negative breast cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01307891 [Last accessed on 30 Jan 2023]

[90] ClinicalTrials.gov. CS1008- in combination with sorafenib compared to sorafenib alone in subjects with advanced liver cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01033240 [Last accessed on 30 Jan 2023]

[91] ClinicalTrials.gov. Phase 1b lymphoma study of AMG 655 in combination with bortezomib or vorinostat. Available from: https://clinicaltrials.gov/ct2/show/NCT00791011 [Last accessed on 30 Jan 2023]

[92] ClinicalTrials.gov. QUILT-2.019: A study of AMG 655 or AMG 479 in combination with gemcitabine for treatment of metastatic pancreatic cancer. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00630552 [Last accessed on 30 Jan 2023]

[93] ClinicalTrials.gov. Phase 1b/2 study of AMG 655 with mFOLFOX6 and bevacizumab for first-line metastatic colorectal cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT00625651 [Last accessed on 30 Jan 2023]

[94] Dubuisson A.Antibodies and derivatives targeting DR4 and DR5 for cancer therapy.Antibodies2017;6:16 PMCID:PMC6698863

[95] Soria JC,Zatloukal P.Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer.J Clin Oncol2011;29:4442-51

[96] von Pawel J,Spigel DR.Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.Clin Lung Cancer2014;15:188-196.e2

[97] Cheng AL,He AR.Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: a phase 2 randomized study.J Hepatol2015;63:896-904

[98] Reck M,Chmielowska E.A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer.Lung Cancer2013;82:441-8

[99] Forero-Torres A,Goldschmidt J.Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.Blood2015;126:2798-804 PMCID:PMC4692140

[100] Fuchs CS,Schwartzberg L.TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: a randomized phase 1b/2 trial.Cancer2013;119:4290-8

[101] Twomey JD,Zhao L,Zhang B.Spatial dynamics of TRAIL death receptors in cancer cells.Drug Resist Updat2015;19:13-21

[102] Yao Y,Liu L.Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance.Front Mol Biosci2020;7:193 PMCID:PMC7468194

[103] Mottaghitalab F,Fatahi Y,Dinarvand R.New insights into designing hybrid nanoparticles for lung cancer: diagnosis and treatment.J Control Release2019;295:250-67

[104] Zakaria AB,Rattier T.Nanovectorization of TRAIL with single wall carbon nanotubes enhances tumor cell killing.Nano Lett2015;15:891-5

[105] Jiang T,Zhu Q.Furin-mediated sequential delivery of anticancer cytokine and small-molecule drug shuttled by graphene.Adv Mater2015;27:1021-8 PMCID:PMC5769919

[106] Arroyo N,Picaud F.Ligand nanovectorization using graphene to target cellular death receptors of cancer cell.Proteins2020;88:94-105

[107] Lotfollahzadeh S,Aznaveh MH.TRAIL/S-layer/graphene quantum dot nanohybrid enhanced stability and anticancer activity of TRAIL on colon cancer cells.Sci Rep2022;12:5851

[108] Huang YJ.TRAIL-functionalized gold nanoparticles selectively trigger apoptosis in polarized macrophages.Nanotheranostics2017;1:326-37 PMCID:PMC5646729

[109] Ke S,Yang P.Gold nanoparticles enhance TRAIL sensitivity through Drp1-mediated apoptotic and autophagic mitochondrial fission in NSCLC cells.Int J Nanomedicine2017;12:2531-51 PMCID:PMC5383076

[110] Birtekocak F,Cevik O.TRAIL conjugated silver nanoparticle synthesis, characterization and therapeutic effects on HT-29 colon cancer cells.Iran J Pharm Res2021;20:45-56 PMCID:PMC8457744

[111] Sur-Erdem I,Pınarbası N.TRAIL-conjugated silver nanoparticles sensitize glioblastoma cells to TRAIL by regulating CHK1 in the DNA repair pathway.Neurol Res2020;42:1061-9

[112] Gallego-Lleyda A,Anel A.Lipid nanoparticles decorated with TNF-related aptosis-inducing ligand (TRAIL) Are more cytotoxic than soluble recombinant TRAIL in sarcoma.Int J Mol Sci2018;19:1449 PMCID:PMC5983602

[113] De Miguel D,Ayuso JM.Improved anti-tumor activity of novel highly bioactive liposome-bound TRAIL in breast cancer cells.Recent Pat Anticancer Drug Discov2016;11:197-214

[114] Miguel D, Gallego-Lleyda A, Anel A, Martinez-Lostao L. Liposome-bound TRAIL induces superior DR5 clustering and enhanced DISC recruitment in histiocytic lymphoma U937 cells.Leuk Res2015;39:657-66

[115] De Miguel D,Ayuso JM.TRAIL-coated lipid-nanoparticles overcome resistance to soluble recombinant TRAIL in non-small cell lung cancer cells.Nanotechnology2016;27:185101

[116] De Miguel D,Ayuso JM.High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles enhances DR5 cross-linking and increases antitumour effect against colon cancer.Cancer Lett2016;383:250-60

[117] Li Q,Guo X.Chemically modified liposomes carrying TRAIL target activated hepatic stellate cells and ameliorate hepatic fibrosis in vitro and in vivo.J Cell Mol Med2019;23:1951-62 PMCID:PMC6378220

[118] Jun H,Kim H.TRAIL & EGFR affibody dual-display on a protein nanoparticle synergistically suppresses tumor growth.J Control Release2022;349:367-78

[119] Thao le Q,Lee C.Doxorubicin-bound albumin nanoparticles containing a TRAIL protein for targeted treatment of colon cancer.Pharm Res2016;33:615-26

[120] Shi Y,Liu J.Oxidative stress-driven DR5 upregulation restores TRAIL/Apo2L sensitivity induced by iron oxide nanoparticles in colorectal cancer.Biomaterials2020;233:119753

[121] Perlstein B,Miller C.TRAIL conjugated to nanoparticles exhibits increased anti-tumor activities in glioma cells and glioma stem cells in vitro and in vivo.Neuro Oncol2013;15:29-40 PMCID:PMC3534416

[122] Belkahla H,Gharbi T.Grafting TRAIL through either amino or carboxylic groups onto maghemite nanoparticles: influence on pro-apoptotic efficiency.Nanomaterials2021;11:502 PMCID:PMC7922020

[123] Wang MS,Xiong YQ,Wang JP.Iron oxide magnetic nanoparticles combined with actein suppress non-small-cell lung cancer growth in a p53-dependent manner.Int J Nanomedicine2017;12:7627-51 PMCID:PMC5655152

[124] Shakil MS,Sarker SR.Iron Oxide Nanoparticles for breast cancer theranostics.Curr Drug Metab2019;20:446-56

[125] Liu H,Chen X.Application of iron oxide nanoparticles in glioma imaging and therapy: from bench to bedside.Nanoscale2016;8:7808-26

[126] Huang K,Zhang C,Hua Z.Improved antitumor activity of TRAIL fusion protein via formation of self-assembling nanoparticle.Sci Rep2017;7:41904 PMCID:PMC5320504

[127] Hadad E,Itzhaki E.Engineering of doxorubicin-encapsulating and TRAIL-conjugated poly(RGD) proteinoid nanocapsules for drug delivery applications.Polymers2020;12:2996 PMCID:PMC7765502

[128] Zhang ZQ.Multiple hyperthermia-mediated release of TRAIL/SPION nanocomplex from thermosensitive polymeric hydrogels for combination cancer therapy.Biomaterials2017;132:16-27

[129] Riehle R,Jhaveri A.Combination nanopreparations of a novel proapoptotic drug - NCL-240, TRAIL and siRNA.Pharm Res2016;33:1587-601

[130] Wang S,Zhong Z.Co-delivery of gambogic acid and TRAIL plasmid by hyaluronic acid grafted PEI-PLGA nanoparticles for the treatment of triple negative breast cancer.Drug Deliv2017;24:1791-800 PMCID:PMC8240989

[131] Jiang X,Wang C.Nanoparticle engineered TRAIL-overexpressing adipose-derived stem cells target and eradicate glioblastoma via intracranial delivery.Proc Natl Acad Sci USA2016;113:13857-62 PMCID:PMC5137687

[132] Lee AL,Wang Y,Fan W.Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles.Mol Biosyst2011;7:1512-22

[133] Skidan I,Thekkedath RV,Degterev A.In vitro cytotoxicity of novel pro-apoptotic agent DM-PIT-1 in PEG-PE-based micelles alone and in combination with TRAIL.Drug Deliv2009;16:45-51 PMCID:PMC3071122

[134] Lim SM,Jiang HH.Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticles.Biomaterials2011;32:3538-46

[135] Yang X,Wu Q,Yi C.TRAIL and curcumin codelivery nanoparticles enhance TRAIL-induced apoptosis through upregulation of death receptors.Drug Deliv2017;24:1526-36 PMCID:PMC8241104

[136] Feng C,Chi L,Gong F.Synthesis, characterization, and in vitro evaluation of TRAIL-modified, cabazitaxel -loaded polymeric micelles for achieving synergistic anticancer therapy.J Biomater Sci Polym Ed2018;29:1729-44

[137] Zhong HH,Li J.TRAIL-based gene delivery and therapeutic strategies.Acta Pharmacol Sin2019;40:1373-85

[138] Wei W,Wu H.Magnetic iron oxide nanoparticles mediated gene therapy for breast cancer - an in vitro study.J Huazhong Univ Sci Technolog Med Sci2006;26:728-30

[139] Li F,Sun J,Ba Q,Shi D.Efficient in vitro TRAIL-gene delivery in drug-resistant A2780/DDP ovarian cancer cell line via magnetofection.J Nanomater2011;2011:1-7

[140] Alvizo-Baez CA,Vilches-Cisneros N,Alcocer-González JM.Systemic delivery and activation of the TRAIL gene in lungs, with magnetic nanoparticles of chitosan controlled by an external magnetic field.Int J Nanomedicine2016;11:6449-58 PMCID:PMC5144894

[141] Miao L,Qiao C.Antitumor effect of human TRAIL on adenoid cystic carcinoma using magnetic nanoparticle-mediated gene expression.Nanomedicine2013;9:141-50

[142] Jiang J,Deng Q.Gold nanoparticles conjugated to the secretable trimeric TRAIL gene promote apoptosis in heat-shocked hepatoma cells.Int J Clin Exp Med2017;10:14047-55

[143] Sharkawi FZ, Ewais SM, Fahmy RH, Rashed LA. PTEN and TRAIL genes loaded zein nanoparticles as potential therapy for hepatocellular carcinoma.J Drug Target2017;25:513-22

[144] Li N,Li C.Polymer Nanoparticles Overcome Drug Resistance by a Dual-Targeting Apoptotic Signaling Pathway in Breast Cancer.ACS Appl Mater Interf2022:23117-28

[145] Vaughan HJ,Radant NP.Poly(beta-amino ester) nanoparticles enable tumor-specific TRAIL secretion and a bystander effect to treat liver cancer.Mol Ther Oncolytics2021;21:377-88 PMCID:PMC8208964

[146] Miao L,Ge J.Antitumor effect of TRAIL on oral squamous cell carcinoma using magnetic nanoparticle-mediated gene expression.Cell Biochem Biophys2014;69:663-72

[147] Pishavar E,Alibolandi M,Hashemi M.Modified PAMAM vehicles for effective TRAIL gene delivery to colon adenocarcinoma: in vitro and in vivo evaluation.Artif Cells Nanomed Biotechnol2018;46:S503-13

[148] Zheng Y,Zeng X.Surface modification of TPGS-b-(PCL-ran-PGA) nanoparticles with polyethyleneimine as a co-delivery system of TRAIL and endostatin for cervical cancer gene therapy.Nanoscale Res Lett2013;8:161 PMCID:PMC3639870

[149] Wang Y,Shao N.Triazine-modified dendrimer for efficient TRAIL gene therapy in osteosarcoma.Acta Biomater2015;17:115-24

[150] Li L,Yang X.Multifunctional “core-shell” nanoparticles-based gene delivery for treatment of aggressive melanoma.Biomaterials2016;111:124-37

[151] Tzeng SY,Hansen SK,Green JJ.Polymeric nanoparticle-based delivery of TRAIL DNA for cancer-specific killing.Bioeng Transl Med2016;1:149-59 PMCID:PMC5365091

[152] Li L,Wu Y.Multifunctional nucleus-targeting nanoparticles with ultra-high gene transfection efficiency for in vivo gene therapy.Theranostics2017;7:1633-49 PMCID:PMC5436517

[153] Song L,Yang S.Novel polyethyleneimine-R8-heparin nanogel for high-efficiency gene delivery in vitro and in vivo.Drug Deliv2018;25:122-31 PMCID:PMC6058572

[154] Xu F,Chang Y.Targeting death receptors for drug-resistant cancer therapy: codelivery of pTRAIL and monensin using dual-targeting and stimuli-responsive self-assembling nanocomposites.Biomaterials2018;158:56-73

[155] Fan H,Xu FJ,Tang GP.in vivo treatment of tumors using host-guest conjugated nanoparticles functionalized with doxorubicin and therapeutic gene pTRAIL.Biomaterials2012;33:1428-36

[156] Sun NF,Tian AL.Nanoliposome-mediated FL/TRAIL double-gene therapy for colon cancer: in vitro and in vivo evaluation.Cancer Lett2012;315:69-77

[157] Liu CH,Hsu FF.A multifunctional nanocarrier for efficient TRAIL-based gene therapy against hepatocellular carcinoma with desmoplasia in mice.Hepatology2018;67:899-913

[158] Luo C,Zhao Y.A novel cationic lipid with intrinsic antitumor activity to facilitate gene therapy of TRAIL DNA.Biomaterials2016;102:239-48 PMCID:PMC5512171

[159] Chen K,Li M.A TRAIL-delivered lipoprotein-bioinspired nanovector engineering stem cell-based platform for inhibition of lung metastasis of melanoma.Theranostics2019;9:2984-98 PMCID:PMC6568176

[160] Lu W,Wan J,Jiang XG.Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration.Cancer Res2006;66:11878-87